An exceptionally potent analog of sandramycin (cas 100940-65-6)

Add time:08/14/2019    Source:sciencedirect.com

The preparation and preliminary evaluation of 2, an analog of sandramycin, are detailed. Although 2 was typically 4–10x less potent than sandramycin against leukemia cell lines, it was found to be 1–10,000x more potent against melanomas, carcinomas, and adenocarcinomas exhibiting typical IC50 values of 200-1 pM and placing it among the most potent agents identified to date.

We also recommend Trading Suppliers and Manufacturers of sandramycin (cas 100940-65-6). Pls Click Website Link as below: cas 100940-65-6 suppliers

Prev:Molecular and cellular pharmacologyCloning and characterization of the porcine gastrin/cholecystokinin type 2 receptor
Next:Synthesis of key sandramycin (cas 100940-65-6) analogs: systematic examination of the intercalation chromophore)